Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00576
|
|||||
| Drug Name |
Telithromycin
|
|||||
| Synonyms |
(1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A; HMR 3647; HMR-3647; HMR3647; Ketek; Ketek (TN); Levviax; RU 66647; RU-66647; RU66647; TEL; Telithromycin (JAN/USAN/INN); Telithromycin [USAN:BAN:INN]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Community acquired pneumonia [ICD11:CA40] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C43H65N5O10
|
|||||
| Canonical SMILES |
CCC1C2(C(C(C(=O)C(CC(C(C(C(=O)C(C(=O)O1)C)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C
|
|||||
| InChI |
InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1
|
|||||
| InChIKey |
LJVAJPDWBABPEJ-PNUFFHFMSA-N
|
|||||
| CAS Number |
CAS 191114-48-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 812 | Topological Polar Surface Area | 172 | ||
| Heavy Atom Count | 58 | Rotatable Bond Count | 11 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 13 | |||
| XLogP |
4.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103323138
,111611540
,12015022
,124766275
,126669903
,134224303
,135253289
,135692562
,139962352
,140277637
,141465063
,144205007
,144205756
,14767066
,14913885
,152198790
,160857220
,164765238
,17181612
,175268627
,179150119
,210279153
,210281475
,223393880
,226396929
,247267318
,252401574
,34667812
,57410165
,633047
,79644204
|
|||||
| ChEBI ID |
CHEBI:29688
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Gadobenate dimeglumine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7. | |||||
| 3 | Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci. 2010 Sep 11;41(1):86-95. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.